- PP405 is Pelage Pharmaceuticals' topical hair growth candidate, targeting follicle stem cell metabolism, not androgens.
- Phase 2a topline was reported positive in 2025; the full dataset is not yet peer-reviewed.
- Not approved anywhere. No launched product exists.
- Mechanically distinct from the antiandrogens: it would not be a substitute for RU-58841 or pyrilutamide, but a different axis entirely.
- Research use only. Nothing here is medical advice.
What PP405 actually is
PP405 is a small molecule in clinical development for androgenetic alopecia by Pelage Pharmaceuticals. Where RU-58841 and pyrilutamide attack the problem at the androgen receptor, PP405 targets the mitochondrial pyruvate carrier (MPC), the shuttle that moves pyruvate into mitochondria for energy production. The hypothesis, in plain terms: dormant hair follicle stem cells sit in a low-metabolism state, and reactivating their energy metabolism pushes them back into the growth cycle. It is a genuinely different mechanism from every antiandrogen on the market or in this catalogue, which is exactly why it has generated interest: it would stack with, rather than duplicate, the androgen-blocking approach.
What the company has reported so far
Pelage reported positive topline results from its Phase 2a study in 2025: the compound was described as well tolerated with efficacy signals in androgenetic alopecia. What has not happened yet is peer-reviewed publication of the full dataset, including exact hair-count changes, placebo comparisons, and adverse-event tables. Until that exists, the correct reading of PP405 is the same discipline we apply to pyrilutamide's China trial: real, encouraging, company-reported, and not yet independently verified.
Status: not approved, not launched
PP405 has no marketing authorisation in any jurisdiction. It is in clinical development, and nothing containing it is for sale as a finished product anywhere legitimate. The only context in which the molecule appears in commerce is as a reference material for laboratory research, and any seller making treatment claims about it is saying things the clinical programme itself has not yet proven.
Where it sits in the research landscape
The hair-loss research space now has three distinct mechanistic axes: androgen receptor blockade (RU-58841, pyrilutamide, clascoterone), metabolic reactivation (PP405, and the earlier minoxidil lineage), and the systemic DHT suppression represented by finasteride and dutasteride. PP405 is the first genuinely hyped compound in the metabolic bucket since minoxidil itself. For researchers, that makes it a reference point worth understanding even before it is available: its reported profile, if the Phase 2 data holds, would make it a stacking option rather than a replacement for antiandrogens.
The honest bottom line
PP405 is promising, mechanistically novel, and very early. It has one positive company-reported topline, no published dataset, no approval, and no long-term safety record. Nothing we sell substitutes for it, and it substitutes for nothing we sell: it operates on a different axis. Until it is approved, any PP405 in circulation is a research material, and it should be treated with exactly the caution we document for the antiandrogens on the RU-58841 side effects page.
Related reading
For the antiandrogen side of the space, start with What Is RU58841? and What Is Pyrilutamide?, or read the head-to-head in RU-58841 vs Pyrilutamide.
Nothing we sell is a licensed medicine, and no treatment or medical claims are made. All products are research compounds sold strictly for laboratory use.